195 related articles for article (PubMed ID: 37428482)
1. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
3. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
4. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
[TBL] [Abstract][Full Text] [Related]
5. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
6. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
7. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
[TBL] [Abstract][Full Text] [Related]
8. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
Malani Shukla N; Casper TC; Ness J; Wheeler Y; Chitnis T; Lotze T; Gorman M; Benson L; Weinstock-Guttmann B; Aaen G; Rodriguez M; Tillema JM; Krupp L; Schreiner T; Mar S; Goyal M; Rensel M; Abrams A; Rose J; Waltz M; Liu T; Manlius C; Waubant E;
Pediatr Neurol; 2023 Aug; 145():125-131. PubMed ID: 37348193
[TBL] [Abstract][Full Text] [Related]
9. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
11. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for people with multiple sclerosis.
Filippini G; Kruja J; Del Giovane C
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
14. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
15. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
Fox RJ; Mehta R; Pham T; Park J; Wilson K; Bonafede M
BMC Neurol; 2022 Jun; 22(1):211. PubMed ID: 35672686
[TBL] [Abstract][Full Text] [Related]
16. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
17. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Moccia M; Affinito G; Berera G; Marrazzo G; Piscitelli R; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
J Neurol; 2022 Dec; 269(12):6504-6511. PubMed ID: 35953597
[TBL] [Abstract][Full Text] [Related]
18. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
19. Current and future trends in multiple sclerosis management: Near East perspective.
Hatem A; El Ayoubi NK; Habahbeh M; Ghanim Z; Al-Naqshbandi M; Raki A; Joudi H; Sahraian MA
Mult Scler Relat Disord; 2023 Aug; 76():104800. PubMed ID: 37307691
[TBL] [Abstract][Full Text] [Related]
20. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
